How Long Does Belumosudil Take to Work for Pulmonary cGVHD?

　　Belumosudil mesylate(brand name Rezurock)is a highly selective ROCK2 kinase inhibitor approved for adult patients with chronic graft-versus-host disease(cGVHD)who have shown an inadequate response to corticosteroids or other systemic therapies.Among the many complications that can follow allogeneic hematopoietic stem cell transplantation,pulmonary cGVHD—often referred to by patients as"lung rejection"—is one of the most challenging.Affected individuals typically experience progressive shortness of breath,persistent dry cough,declining exercise tolerance,and a steady deterioration in pulmonary function tests.Naturally,one of the first questions patients ask is:how long before I notice improvement on belumosudil?

　　It is essential to understand that belumosudil is not a fast-acting rescue medication.Pulmonary cGVHD is driven by prolonged,immune-mediated injury accompanied by ongoing airway inflammation and progressive fibrosis.Belumosudil works by modulating the dysregulated immune response and suppressing pro-inflammatory and pro-fibrotic signaling pathways,thereby slowing tissue damage at its source.This mechanism requires time to translate into measurable clinical benefit and cannot produce noticeable changes within just a few days of starting therapy.

　　Based on clinical trial data and real-world experience,some cGVHD patients begin to observe a favorable trend within several weeks to a few months after initiating belumosudil.However,for those with lung involvement,efficacy should never be judged solely by short-term fluctuations in subjective symptoms.A proper assessment integrates pulmonary function testing(particularly changes in FEV1),disease activity scores,and the overall trajectory of systemic manifestations.For many patients,a meaningful treatment response may look less like a dramatic rebound in lung function and more like stabilization of respiratory symptoms and a clear deceleration in the rate of pulmonary decline—which itself signifies that disease progression is being curbed.

　　Patients should also set realistic expectations.Pulmonary cGVHD is a chronic,progressive condition,particularly when significant lung function impairment is already present at the time of treatment initiation.In such cases,the primary therapeutic goal is to control active immune inflammation and halt or slow further damage rather than to reverse established,irreversible fibrosis.Therefore,it is inappropriate to evaluate drug efficacy after only a few days or one to two weeks of therapy.Instead,patients should follow their transplant team's scheduled follow-up intervals for staged assessments.

　　In summary,belumosudil represents an important therapeutic option for patients battling pulmonary cGVHD,but its benefits emerge gradually.Adhering to the prescribed regimen,monitoring lung function at regular intervals,and maintaining close communication with the transplant care team are the keys to achieving the best possible outcome.